Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

J&J reportedly asked COVID-19 vaccine developers to study blood clot risks  

By Brian Buntz | April 16, 2021

Coronavirus vaccine

[Image courtesy of Wikipedia]

Johnson & Johnson (NYSE:JNJ) privately contacted other COVID-19 vaccine makers last week to gauge their interest in studying blood clot risks, according to a Wall Street Journal report. Specifically, the company asked whether its rivals — AstraZeneca, Moderna and Pfizer— had new information about blood clots following vaccination and if they were interested in forming an external panel to examine the issue, according to the article citing anonymous sources. 

None of the four companies have confirmed nor denied the report. 

J&J researchers did state in NEJM that there is insufficient evidence to link six cases of cerebral venous sinus thrombosis (CVST) paired with low platelet counts to the company’s COVID-19 vaccine. Approximately seven million people in the U.S. have received the vaccine. 

AstraZeneca (LON:AZN) is said to have been interested in allying with J&J to study vaccine benefits and risks. Pfizer and Moderna apparently didn’t. According to federal regulators, cases of CVST haven’t been observed in recipients of the Moderna and Pfizer vaccines. 

Some physicians suspect that AstraZeneca’s ChAdOx1 nCoV-19 vaccine can lead to rare cases of acute thrombocytopenia and thrombosis, although a causal association has not been established, as another recent NEJM article concluded. 

Last September, nine vaccine developers, including J&J, Pfizer and Moderna, pledged to ensure their vaccines were safe and effective before filing for regulatory authorization. 

In the EU and U.K., blood clots affecting a small number of AstraZeneca recipients have led to constrained use of the ChAdOx1 nCoV-19 vaccine, which the company developed jointly with Oxford University. 


Filed Under: Infectious Disease
Tagged With: AstraZeneca plc, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, Janssen Pharmaceutical Cos., Johnson & Johnson
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Pfizer
Pfizer shares positive top-line data from Phase 3 Study of pneumococcal vaccine
Vaccine
The most common monkeypox vaccine side effects
FDA logo
FDA grants emergency use authorization to Jynneos monkeypox vaccine to support ‘dose sparing’
JYNNEOS vaccine
Jynneos vaccine: The best weapon against monkeypox?

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50